: ………………………………………………………………………………………. 8 8 Table S2 : ……………………………………………………………………………………… 9 9 Genotype MTBDRplus. Baseline chest x-ray showed right hilar infiltrate, consolidation in the right apex 51 and cavitation in the left apex. He initiated a standardised regimen including moxifloxacin, 52 pyrazinamide, kanamycin, ethionamide, isoniazid and terizidone, as per national guidelines within two 53 days of diagnosis. Isolates taken at diagnosis and initiation of treatment were culture-positive and 54 susceptible to ofloxacin and amikacin based on routine phenotypic DST (National Health Laboratory 55
Services, Green Point, South Africa). Isoniazid was withdrawn 28 days after treatment initiation. 56
Follow-up routine sputum specimens taken 42 days and 3.4 months after treatment initiation were acid-57 fast bacilli (AFB) smear and culture negative (Table S1 ). Four subsequent sputum specimens collected 58 four to eight months after treatment initiation were smear-and culture-positive. Kanamycin was stopped 59 six months after treatment initiation. The sputum specimen taken six months after initiation of standard 60 treatment showed phenotypic resistance to ofloxacin using phenotypic DST and the patient was 61 classified as failure of treatment. Month six chest x-ray showed extensive fibrosis in the left lung and 62 cavitation in both apices. At month eight, treatment was revised to include high-dose isoniazid (800 63 mg), ethambutol, pyrazinamide, terizidone, linezolid, para-aminosalicylic acid (PAS) and kanamycin. 64
Bedaquiline was added 22 days later and administered for six months per the South African Bedaquiline 65
Clinical Access Program. 9 The patient was admitted at a TB inpatient facility for the first two months 66 of bedaquiline treatment. By examination of the patient's treatment card and patient interview, 67 adherence to bedaquiline during both in-patient and out-patient treatment was subjectively assessed as 68 good, although strict direct observation of treatment was not practised. Pyrazinamide and ethambutol 69 were stopped at 2.3 months following revised regimen initiation due to persistent arthralgia and changes 70 in vision. The patient refused kanamycin at month six for a duration of 2.4 months after more than 71 twelve months of injectable treatment. Kanamycin and high-dose isoniazid were stopped at 13 months 72 (isoniazid due to vision problems). The physician decided to stop all treatment at 15.7 months after 73 which the patient was transitioned to palliative care and died seven months later. All sputum cultures 74 subsequent to stopping of all treatment were positive. 75 which confers resistance to fluoroquinolones, suggests that the classification of fluoroquinolone 88 susceptibility by phenotypic DST performed at the routine laboratory on the same isolate was incorrect. 89
The isolate taken 7.2 months after treatment initiation (isolate B) did not show amplification of 90 resistance, but showed the loss of a variant in rpoC (A734G) (Table S2, Figure S1 ). According to the 91 WGS data, the patient received only two potentially effective drugs (kanamycin and terizidone) (Figure  92 1). Phenotypic resistance to ofloxacin was first detected by the routine laboratory on the specimen 93 collected 6 months after treatment initiation. Targeted deep sequencing (TDS) of isolate B did not detect 94 any underlying variants in Rv0678, the gene associated with resistance to bedaquiline. (Table S3 ) despite phenotypic susceptibility to bedaquiline and genotypic susceptibility on WGS. In the 104 isolate collected one week after bedaquiline treatment was stopped (isolate D), WGS and TDS showed 105 that the Rv0678 192 variant was fixed and TDS showed the presence of multiple low frequency (>0.1%) 106 indels (insertions and deletions) in codons 194 to 198 in Rv0678. In addition, a fixed variant in Rv2839c 107 (S347P) was also observed by WGS (Table S2) . Isolate D was also phenotypically resistant to 108 bedaquiline. Subsequently, the 192 C insertion decreased to 0.1% of reads in isolate F (taken 12.3 109 months after the start of the individualized regimen and five months after the cessation of bedaquiline) 110 and was replaced with a different Rv0678 variant (GA insertion at gene position 138) and a second rpoB 111 variant (S582A) according to WGS. In the subsequent isolates taken 15.7 months (isolate G) and 21.7 112 months (isolate H) after initiation of the revised regimen, WGS and TDS showed the systematic decrease 113 of the Rv0678 138 GA insertion over time and the gain of a third Rv0678 variant (G insertion at position 114 138). WGS showed the emergence of an rpoC (V483G) variant in this isolate. These Rv0678 138 G 115 insertion and rpoC V483G were found with a variant frequency of 96% in the last isolate taken. The 116 systematic gain and loss of Rv0678 variants identified by WGS was confirmed by Sanger sequencing 117 (data not shown). All isolates with a variant frequency of >1% in Rv0678 were resistant to bedaquiline 118 at a concentration of 1 µg/ml in MGIT media. 119
The identification of a subpopulation of bacilli harbouring a variant in Rv0678 10 weeks after addition 120 of bedaquiline suggest that bedaquiline resistance emerged soon after its inclusion in the revised MDR-121 TB regimen and was subsequently selected as treatment continued. Following the withdrawal of 122 bedaquiline a further gain and loss of Rv0678 variants were observed over the course of the long half 
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